---
title: "KMTS.US (KMTS.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/KMTS.US/news.md"
symbol: "KMTS.US"
name: "KMTS.US"
parent: "https://longbridge.com/en/quote/KMTS.US.md"
datetime: "2026-03-04T06:52:05.046Z"
locales:
  - [en](https://longbridge.com/en/quote/KMTS.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/KMTS.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/KMTS.US/news.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/KMTS.US/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/KMTS.US/news.md)


# KMTS.US (KMTS.US) — Related News

### [Global peripheral vascular devices market growing at a CAGR of ~6% till 2032 due to high demand for minimally invasive treatments.](https://longbridge.com/en/news/277691402.md)
*2026-03-03T22:48:32.000Z*
> The peripheral vascular devices market on a global scale is witnessing consistent growth due to the increasing prevalenc

### [Chronic kidney disease market set to grow (2025-2034) due to increased demand for early diagnosis and treatments, driven by diabetes, hypertension, and aging populations.](https://longbridge.com/en/news/277690069.md)
*2026-03-03T22:32:20.000Z*
> The ongoing expansion of the chronic kidney disease market is fueled by the increasing occurrence of diabetes and hypert

### [AI analysis of eye photos in premature infants can help detect serious lung and heart conditions, identifying risk earlier.](https://longbridge.com/en/news/277650936.md)
*2026-03-03T15:48:04.000Z*
> A recent study indicates that regular, noninvasive retinal imaging may assist in identifying critical complications soon

### [Mauna Kea Technologies ernennt Benoit Chardon zum Chief Commercial Officer für CellTolerance](https://longbridge.com/en/news/274846203.md)
*2026-02-04T16:52:56.000Z*
> Mauna Kea Technologies SA has appointed Benoit Chardon as the Fractional Chief Commercial Officer. Chardon will oversee 

### [Kestra Medical Technologies Ltd. Officer Brian Daniel Webster Reports Sale of Common Shares](https://longbridge.com/en/news/273073321.md)
*2026-01-20T11:04:36.000Z*
> Brian Daniel Webster, Director and Officer of Kestra Medical Technologies Ltd., reported the sale of common shares of th

### [Kestra Medical Tech | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 22.4 M](https://longbridge.com/en/news/268077817.md)
*2025-12-01T12:08:39.000Z*
### [Kestra Medical Tech | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 19.37 M](https://longbridge.com/en/news/257159895.md)
*2025-09-12T20:19:01.000Z*
### [Kestra Medical Tech | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 19.37 M](https://longbridge.com/en/news/256984764.md)
*2025-09-11T20:18:13.000Z*
### [Kestra Medical Tech | 10-K: FY2025 Revenue: USD 59.8 M](https://longbridge.com/en/news/249028954.md)
*2025-07-17T20:08:48.000Z*
### [Kestra Medical Tech | 8-K: FY2025 Q4 Revenue: USD 17.23 M](https://longbridge.com/en/news/248669713.md)
*2025-07-15T20:13:18.000Z*